AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9503938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8408980 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 39
Study 8408980 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 39
Study 8408980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MAOIs
Number of subjects: 39
Study 3518787 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol‐impregnated chromic catgut
Number of subjects: 737
Study 3518787 — intervention group
Group type: COMPARATOR
Intervention: Untreated chromic catgut
Number of subjects: 737
Study 29114041 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 58
Study 29114041 — intervention group
Group type: COMPARATOR
Intervention: Antiproteinuric therapy alone
Number of subjects: 58
Study 27519593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra E.R.A.S.
Number of subjects: 765
Study 27519593 — intervention group
Group type: COMPARATOR
Intervention: Classic E.R.A.S.
Number of subjects: 765
Study 26256140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program over 10 weeks
Number of subjects: 42
Study 23777506 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg with each meal for 1 week
Number of subjects: 54
Study 23777506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-diabetic agent for 1 week)
Number of subjects: 54
Study 20620320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (ceftriaxone and metronidazole, once daily for a minimum of 5 days)
Number of subjects: 102
Study 20620320 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics (amoxicillin/clavulanate, after tolerating a regular diet for 7 days)
Number of subjects: 102
Study 19128668 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel
Number of subjects: 20
Study 19128668 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 20
Study 16644316 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (81 mg)
Number of subjects: 50
Study 16644316 — intervention group
Group type: COMPARATOR
Intervention: Standard aspirin (81 mg)
Number of subjects: 50
Study 16644316 — intervention group
Group type: COMPARATOR
Intervention: Optical aggregometry with arachidonic acid
Number of subjects: 50
Study 16644316 — intervention group
Group type: COMPARATOR
Intervention: Optical aggregometry with adenosine diphosphate
Number of subjects: 50
Study 12802741 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine 3 x 8 mg t.i.d. for 6 months
Number of subjects: 166
Study 12802741 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 166
Study 12802741 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine
Number of subjects: 166
Study 10780937 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Glutamine (0.5 g x kg(‐1) x day(‐1) for 2 days)
Number of subjects: 4
Study 10780937 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous Ala‐Gly
Number of subjects: 4
Study 8809523 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity knee extensor strength training
Number of subjects: 11
Study 8809523 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 11
Study 8809523 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 11
Study 1652611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 10 mg every 6 hr plus placebo
Number of subjects: 0
Study 1652611 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prochlorperazine 10 mg every 6 hr
Number of subjects: 0
Study 1652611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol and prochlorperazine, each 10 mg every 6 hr
Number of subjects: 0
Study 6808550 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0
Study 6808550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31818266 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine dialysis initiation at eGFR 7 ml/min/1.73 m2
Number of subjects: 0
Study 31818266 — intervention group
Group type: COMPARATOR
Intervention: Deferred dialysis initiation at eGFR 5 ml/min/1.73 m2 or less
Number of subjects: 0
Study 31818266 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine dialysis initiation
Number of subjects: 0
Study 31818266 — intervention group
Group type: COMPARATOR
Intervention: Deferred dialysis initiation
Number of subjects: 0
Study 27893880 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families program
Number of subjects: 119
Study 27893880 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 119
Study 26545541 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching program performed once a week for eight weeks
Number of subjects: 180
Study 26545541 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching program performed twice a week for eight weeks
Number of subjects: 180
Study 26545541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching program)
Number of subjects: 180
Study 24267238 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-335 (fenofibric acid)
Number of subjects: 0
Study 21526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab administered monthly
Number of subjects: 1208
Study 21526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab administered monthly
Number of subjects: 1208
Study 21526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab administered as needed
Number of subjects: 1208
Study 21526923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab administered as needed
Number of subjects: 1208
Study 21526923 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1208
Study 21526923 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 1208
Study 19525191 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium‐90 ibritumomab tiuxetan
Number of subjects: 41
Study 19525191 — intervention group
Group type: COMPARATOR
Intervention: Short-course rituximab/chemotherapy
Number of subjects: 41
Study 16458976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 103
Study 16458976 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 103
Study 15673996 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of standardized turmeric extract taken daily for 8 weeks
Number of subjects: 207
Study 15673996 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of standardized turmeric extract taken daily for 8 weeks
Number of subjects: 207
Study 15673996 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 207
Study 11350464 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 500 microg
Number of subjects: 34
Study 11350464 — intervention group
Group type: COMPARATOR
Intervention: Saline 1 mL
Number of subjects: 34
Study 9451487 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-ketamine/midazolam
Number of subjects: 41
Study 9451487 — intervention group
Group type: COMPARATOR
Intervention: racemic ketamine/midazolam
Number of subjects: 41
Study 8623820 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and misoprostol
Number of subjects: 86
Study 8623820 — intervention group
Group type: EXPERIMENTAL
Intervention: Other subjects (not complete abortion)
Number of subjects: 86
Study 2266674 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (20 mg/kg) post-dialysis for up to six months
Number of subjects: 82
Study 2266674 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 82
Study 7008244 — intervention group
Group type: EXPERIMENTAL
Intervention: F.X group (anticoagulant dosage based on F.X)
Number of subjects: 42
Study 7008244 — intervention group
Group type: COMPARATOR
Intervention: PT group (anticoagulant dosage according to PT)
Number of subjects: 42
Study 7008244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PT and F.X)
Number of subjects: 42
Study 30896226 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX GBG Alone
Number of subjects: 27
Study 30896226 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX GBG + PATHS
Number of subjects: 27
Study 30896226 — intervention group
Group type: COMPARATOR
Intervention: Standard setting (control)
Number of subjects: 27
Study 28410419 — intervention group
Group type: EXPERIMENTAL
Intervention: ST analysis during labor
Number of subjects: 1097
Study 28410419 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial T/QRS baseline
Number of subjects: 1097
Study 26669548 — intervention group
Group type: EXPERIMENTAL
Intervention: Roughened surface implants
Number of subjects: 50
Study 26669548 — intervention group
Group type: COMPARATOR
Intervention: Machined/turned surface implants
Number of subjects: 50
Study 24961193 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention
Number of subjects: 540
Study 24961193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 540
Study 22739141 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH; 150 U/kg)
Number of subjects: 48
Study 22739141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium (1 mg/kg)
Number of subjects: 48
Study 22739141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (120 IU/kg)
Number of subjects: 48
Study 22739141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adomiparin sodium (125 IU/kg)
Number of subjects: 48
Study 22739141 — intervention group
Group type: EXPERIMENTAL
Intervention: All heparin treatments
Number of subjects: 48
Study 19846798 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg/day)
Number of subjects: 170
Study 19846798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 17346654 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based food portion training program (CFPT)
Number of subjects: 76
Study 17346654 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants estimating portion sizes before CFPT training)
Number of subjects: 76
Study 15987460 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (HT)
Number of subjects: 4155
Study 15987460 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of HT (Control)
Number of subjects: 4155
Study 12233878 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial functional status (measured by Health Assessment Questionnaire (HAQ) score)
Number of subjects: 1269
Study 12233878 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining HAQ score
Number of subjects: 1269
Study 12233878 — intervention group
Group type: COMPARATOR
Intervention: No change or improvement in HAQ score
Number of subjects: 1269
Study 12233878 — intervention group
Group type: COMPARATOR
Intervention: Comparison to US population
Number of subjects: 1269
Study 9001416 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) plus cytosine arabinoside (ara‐C)
Number of subjects: 174
Study 9001416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin (ACR) plus cytosine arabinoside (ara‐C)
Number of subjects: 174
Study 9001416 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission after one or two induction courses
Number of subjects: 174
Study 9001416 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary neoplasms diagnosed simultaneously with or after AML diagnosis
Number of subjects: 174
Study 9001416 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients alive and in complete remission 5 years after AML diagnosis
Number of subjects: 174
Study 8510086 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20-40 mg three times daily
Number of subjects: 0
Study 8510086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25-100 mg four times daily
Number of subjects: 0
Study 3431880 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 28
Study 3431880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31268194 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized fortification (IF) group
Number of subjects: 51
Study 31268194 — intervention group
Group type: COMPARATOR
Intervention: Standard fortification group
Number of subjects: 51
Study 28272119 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 198
Study 28272119 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 198
Study 27787895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided, single-injection, femoral nerve block followed by continuous fascia iliaca block
Number of subjects: 161
Study 27787895 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesics
Number of subjects: 161
Study 24987525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention - Raising the salience of personal investment in weight-loss surgery
Number of subjects: 91
Study 24987525 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study 24987525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention - Weight loss measurement
Number of subjects: 91
Study 24987525 — intervention group
Group type: COMPARATOR
Intervention: Control - Weight loss measurement
Number of subjects: 91
Study 23109014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy
Number of subjects: 30
Study 23109014 — intervention group
Group type: COMPARATOR
Intervention: LPV/r-based HAART
Number of subjects: 30
Study 20232607 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paired physical activity and nutrition messages via e-mail for 12 weeks
Number of subjects: 1043
Study 20232607 — intervention group
Group type: COMPARATOR
Intervention: Bulk e-mail messages at the conclusion of the intervention (Control)
Number of subjects: 1043
Study 18416885 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH) 10 g in 25 mL liquid formulation
Number of subjects: 147
Study 18416885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25 mL liquid containing xanthan)
Number of subjects: 147
Study 15665549 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg three times a day for 2 months
Number of subjects: 39
Study 15665549 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg three times a day for 2 months
Number of subjects: 39
Study 11839142 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTI + protease inhibitor
Number of subjects: 0
Study 10084409 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) 4.5 g i.v. every six hours (n = 75)
Number of subjects: 150
Study 10084409 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (I/C) 500 mg i.v. every six hours (n = 75)
Number of subjects: 150
Study 10084409 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T)
Number of subjects: 150
Study 10084409 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (I/C)
Number of subjects: 150
Study 7781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (50 to 60 Gy recommended)
Number of subjects: 0
Study 7781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 7781402 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative thoracic radiation fractionation schedules (accelerated hyperfractionation)
Number of subjects: 0
Study 7781402 — intervention group
Group type: COMPARATOR
Intervention: Concurrent and alternating chemotherapy strategies
Number of subjects: 0
Study 1685506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 163
Study 1685506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-plus-metronidazole
Number of subjects: 163
Study 1685506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemoprophylaxis)
Number of subjects: 163
Study 6650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment of 400 mg cholesterol per day with exercise (MX)
Number of subjects: 23
Study 6650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment of 1400 mg cholesterol per day with exercise (HX)
Number of subjects: 23
Study 6650444 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment of 1400 mg cholesterol per day without exercise (HS)
Number of subjects: 23
Study 6650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and sedentary group data at each level of dietary cholesterol
Number of subjects: 23
Study 30720850 — intervention group
Group type: COMPARATOR
Intervention: Single use dialyzers (10 HD sessions)
Number of subjects: 10
Study 30720850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer reuse (30 HD sessions)
Number of subjects: 10
Study 30720850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer reuse
Number of subjects: 10
Study 28787388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (2 daily oral doses of 2 × 10 CFUs for 5 days)
Number of subjects: 150
Study 28787388 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 daily doses for 5 days)
Number of subjects: 150
Study 28787388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 150
Study 28787388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 26906708 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon catheter dilatation
Number of subjects: 189
Study 26906708 — intervention group
Group type: COMPARATOR
Intervention: Nasolacrimal duct intubation
Number of subjects: 189
Study 24214140 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brimonidine (0.2 %) twice daily for 6 months
Number of subjects: 30
Study 24214140 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 30
Study 22303998 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (sleep education and counseling session)
Number of subjects: 236
Study 22303998 — intervention group
Group type: COMPARATOR
Intervention: Control (no psychoeducational intervention)
Number of subjects: 236
Study 20069963 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitro ceramic
Number of subjects: 15
Study 20069963 — intervention group
Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 15
Study 17450962 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous skilled model observation and self-modeling
Number of subjects: 53
Study 17450962 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 53
Study 15150726 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-live virus combination vaccine, subcutaneous vaccination
Number of subjects: 0
Study 15150726 — intervention group
Group type: COMPARATOR
Intervention: Nonvaccinated controls
Number of subjects: 0
Study 11772828 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block with 10 mL of 0.5% bupivacaine
Number of subjects: 30
Study 11772828 — intervention group
Group type: COMPARATOR
Intervention: Suprascapular nerve block with 10 mL of 0.9% saline (placebo)
Number of subjects: 30
Study 10518850 — intervention group
Group type: EXPERIMENTAL
Intervention: Active unit (electronic anesthesia)
Number of subjects: 100
Study 10518850 — intervention group
Group type: COMPARATOR
Intervention: Control unit (non-working electronic anesthesia)
Number of subjects: 100
Study 7807622 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management using trained community health workers with thrice weekly home visits and treatment based on WHO recommendations
Number of subjects: 481
Study 7807622 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral system established from the community to a tertiary centre
Number of subjects: 481
Study 2561409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 x 4 mg daily by inhalation)
Number of subjects: 117
Study 326301 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atenolol (1%, 2%, and 4%)
Number of subjects: 16
Study 326301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31813384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (56 g) within a hypoenergetic diet
Number of subjects: 64
Study 31813384 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional peanuts (56 g) within a hypoenergetic diet
Number of subjects: 64
Study 31813384 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypoenergetic diet without peanuts)
Number of subjects: 64
Study 30913926 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm nature films during colonoscopy
Number of subjects: 0
Study 30913926 — intervention group
Group type: COMPARATOR
Intervention: Control (standard examination room without films)
Number of subjects: 0
Study 29073603 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional coronary artery bypass (CCAB)
Number of subjects: 30
Study 29073603 — intervention group
Group type: EXPERIMENTAL
Intervention: Off‐pump coronary artery bypass grafting (OPCAB)
Number of subjects: 30
Study 25149179 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPONE) 20 mg
Number of subjects: 52
Study 25149179 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PN) 25 mg
Number of subjects: 52
Study 22999778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenobarbital (10 mg/kg in 100 mL normal saline)
Number of subjects: 102
Study 22999778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL normal saline)
Number of subjects: 102
Study 21516008 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy using a far infrared rays heating element
Number of subjects: 48
Study 21516008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heat therapy)
Number of subjects: 48
Study 18068281 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin +/- granulocyte-colony-stimulating factor
Number of subjects: 0
Study 18068281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 18068281 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Number of subjects: 0
Study 18068281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (azacytidine and decitabine)
Number of subjects: 0